Low molecular weight heparin treatment decreases MMP-9 plasma activity in patients with abdominal aortic aneurysm.
Level II
Where this comes from
- Record sourced from PubMed, PMID 17964826.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Large abdominal aortic aneurysms (AAAs) are associated with coagulation abnormalities, which are significantly reduced by low molecular weight heparin (LMWH). Considering anti-inflammatory properties of heparin we verified, whether LMWH influences MMP-2/-9 in AAA patients. The study involved 26 AAA individuals, 10 patients with coagulation abnormalities received LMWH and 16 were a control group. The plasma activity of MMP-2/-9 was measured using zymography. We found that, in addition to the reduction of coagulation abnormalities, LMWH treatment was associated with the decreased MMP-9 but not MMP-2 activity. Therefore, LMWH use could be considered as a valuable pretreatment before an elective aneurysm repair.
Medical subject headings
- Anticoagulants
- Aortic Aneurysm, Abdominal
- Heparin, Low-Molecular-Weight
- Matrix Metalloproteinase 9